[Results in the treatment of acute granulocytic leukemias using a combination of daunorubicine-cytosine arabinoside-cyclophosphamide. Apropos of 35 cases].
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006027:Glycosides / Q000627:therapeutic use; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D006027:Glycosides; D003561:Cytarabine; D003520:Cyclophosphamide; D003630:Daunorubicin
Résultats du traitement des leucémies aiguës granulocytaires par l'association daunorubicine - cytosine arabinoside - cyclophosphamide. A propos de 35 observations